Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press March 20, 2012, 10:18AM ET

Court throws out Prometheus patent

The Supreme Court has tossed out a medical patent for Prometheus Laboratories, a decision that could affect the burgeoning field of personalized medicine.

The justices on Tuesday unanimously agreed that the patent held by the company -- owned by Switzerland-based Nestle -- was invalid.

The patent covers a blood test that helps doctors determine the proper dosage for a drug, thiopurine, to treat autoimmune illnesses. The Minnesota-based Mayo Clinic had challenged the patent, which is keeping them from marketing its own test.

Courts have been fighting over whether the Prometheus test had patented a natural phenomenon, which cannot be patented.

The high court in an opinion written by Justice Stephen Breyer said the Prometheus blood test used "unpatentable" natural laws.

BW Mall - Sponsored Links

Buy a link now!